Cachet Pharmaceutical Co Ltd

Cachet Pharmaceutical maintains a debt-to-equity ratio of 0.49, indicating a relatively conservative capital structure. The company's liquidity position is assessed as medium, with a current ratio of 1.75, suggesting it can cover short-term obligations but with limited excess capacity. The price-to-book ratio of 0.94 implies that the company's market value is slightly below its book value, while the price-to-tangible-book ratio is identical, indicating no significant intangible asset premium.

Profitability metrics show a return on equity (ROE) of 2.56% and a return on assets (ROA) of 0.87%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The company's net income of 111,378,720 CNY is modest relative to its revenue of 19,525,150,160 CNY, with a net margin of 0.57%. This suggests that the company is not generating strong returns on its operations compared to industry benchmarks.

Geographically, Cachet Pharmaceutical's revenue is concentrated in China, with no disclosed international operations. The company's exposure to a single market increases its vulnerability to domestic regulatory changes and economic fluctuations. No segment-specific revenue breakdown is available, but the lack of diversification is a notable risk factor.

The company's growth trajectory is mixed. While the trailing twelve months (TTM) revenue of 19,525,150,160 CNY is below the analyst estimate of 23,256,135,890 CNY, the free cash flow of 57,063,070 CNY indicates some operational flexibility. However, the capital expenditure of -22,794,790 CNY suggests a reduction in investment, which could limit future growth potential.

Risk factors include a negative net cash position after subtracting total debt, which raises concerns about liquidity. The company's dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted figures. However, the absence of a strong balance sheet and low profitability metrics suggest that the company may face pressure to raise additional capital in the future.

Recent events include the filing of financial data for the latest fiscal period, which shows a decline in operating income to 281,488,130 CNY from previous periods. No recent earnings call transcripts or major announcements have been disclosed, indicating a lack of significant corporate activity in the near term.

Cachet Pharmaceutical Co Ltd (002462.SZ) has undergone a significant update to its corporate taxonomy, with its primary activity now formally classified as "Pharmaceuticals & Medical Research" within the broader "Healthcare" economic sector. This structural clarification, marked as a medium-severity change, establishes a definitive baseline for the company's operational identity, moving from an unclassified state to a specific industry designation. Alongside the sectoral reclassification, the company's risk profile has been initialized with specific assessments. The dilution risk is now rated as "low," indicating a stable capital structure with minimal threat of share value erosion from new issuances. Conversely, the liquidity risk has been assessed as "medium," suggesting that while the company maintains operational solvency, there may be moderate constraints or volatility in its short-term cash flow management. These new risk and classification metrics provide a clearer framework for investors and analysts to evaluate Cachet Pharmaceutical's position within the healthcare market. The low dilution risk is a positive signal for existing shareholders, implying that management is likely prioritizing capital efficiency. However, the medium liquidity risk warrants attention, as it may impact the company's ability to fund immediate research and development initiatives or navigate short-term market fluctuations. Currently, the company is followed by two analysts, though it holds no index memberships and has no reported top holders or officers in the available data. The establishment of these fundamental risk and sector metrics serves as a critical first step in building a comprehensive financial profile for Cachet Pharmaceutical, enabling more precise comparative analysis against peers in the pharmaceutical and medical research space.